 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- BVX001 / BiVictriX Therap
BVX001, a Bispecific ADC Targeting CD7-Positive AML with Favorable Toxicity Profile, Exhibits Significant Efficacy in Primary Patient Samples and PDX-Models (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5290;
In contrast, Mylotarg
- Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5227;
Taken together, the novel CD7-targeting ADC huTH69-DE-vcMMAE showed an outstanding high degree of developability, binds a unique CD7 epitope, triggers a unique set of effector functions and demonstrated potent antitumor activity in vivo. The described ADC is a promising leading candidate for entering further clinical development.
- A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5620;
Together, the novel ADC CD7-DE-vcMMAE showed a unique set of Fc effector functions, potent direct growth inhibitory effects, bystander killing activity and efficacy in xenograft models of T-ALL. These results exhibit CD7-DE-vcMMAE as a promising therapeutic strategy and form the basis for new approaches in the treatment of T-ALL.